Health / Rare Diseases

Novo Nordisk Acquires Zaltenibart to Enhance Rare Disease Treatment Portfolio

Novo Nordisk has entered into an asset purchase and license agreement with Omeros Corporation to acquire zaltenibart (OMS906), a clinical-stage MASP-3 inhibitor. This acquisition aims to enhance Novo Nordisk's rare disease portfolio by deve...